Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RG-1068 RepliGen.

Glen Wheeler1

  • 1editor@greyowltutor.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 11, 2003
PubMed
Summary
This summary is machine-generated.

RG-1068, a synthetic secretin hormone, is being developed as a potential autism treatment. This drug candidate entered phase III clinical trials in 2002 after receiving Fast Track designation for pediatric autism.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glutamate as an extracellular signalling molecule in unicellular protists.

Current biology : CB·2026
Same author

A source or sink of carbon dioxide? Understanding the role of extracellular carbonic anhydrase in carbon acquisition by algal cells.

The New phytologist·2026
Same author

Nitrogen status exerts dynamic control over phosphorus sensing and acquisition via PSR1 in colimited marine diatoms.

Science advances·2025
Same author

Abiotic Stress-Induced Chloroplast and Cytosolic Ca<sup>2+</sup> Dynamics in the Green Alga Chlamydomonas reinhardtii.

Plant, cell & environment·2025
Same author

Evolutionary genomics of the emergence of brown algae as key components of coastal ecosystems.

Cell·2024
Same author

Latitudinal gradients and ocean fronts strongly influence protist communities in the southern Pacific Ocean.

FEMS microbiology ecology·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Endocrinology
  • Neuroscience
  • Pharmacology

Background:

  • Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition.
  • Secretin is a naturally occurring human hormone involved in digestive and metabolic regulation.
  • RG-1068 is a synthetic analog of human secretin.

Purpose of the Study:

  • To evaluate the safety and efficacy of RG-1068 for the treatment of autism.
  • To investigate the potential therapeutic effects of secretin in individuals with ASD.

Main Methods:

  • RG-1068 is a synthetic secretin analog.
  • The drug received Fast Track designation for pediatric autism in September 2001.
  • Phase III clinical trials commenced in February 2002.

Related Experiment Videos

Main Results:

  • Data on efficacy and safety from phase III trials are pending.
  • The study aims to determine if RG-1068 can alleviate core symptoms of autism.

Conclusions:

  • RG-1068 represents a novel therapeutic approach for autism.
  • Further clinical investigation is required to establish its role in autism management.